Iterum Therapeutics plc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
Ireland
Business Address
3 DUBLIN LANDINGS, DUBLIN 1, L2, D01 H104
Mailing Address
3 DUBLIN LANDINGS, DUBLIN 1, L2, D01 H104
Phone
(872) 225-6077
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2024
$50.23M
Stockholders' Equity
$-1.26
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 18, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | January 2, 2026 | View on SEC |
| 8-K Current report of material events | December 12, 2025 | View on SEC |
| 4 Insider stock transaction report | November 20, 2025 | View on SEC |
| 8-K Current report of material events | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
Material Events
8-K
Bankruptcy
March 31, 2026
High Impact
- FDA approval of ORLYNVAH for urinary tract infections achieved on October 25, 2024
- Company has initiated formal liquidation proceedings in the High Court of Ireland
8-K
Bankruptcy
March 27, 2026
High Impact
- FDA approval of ORLYNVAH™ achieved on October 25, 2024
- Company has filed a petition for liquidation in the Irish High Court
8-K
Financial Distress
March 3, 2026
High Impact
- Nasdaq notified Iterum Therapeutics of intent to delist its stock on February 24, 2024, due to low stock price and market value.
- The company is exploring strategic options including a potential wind-down of operations, bankruptcy, or liquidation.
8-K
Financial Distress
March 2, 2026
High Impact
- Iterum Therapeutics (ITRM) faces imminent Nasdaq delisting due to unmet listing standards.
- The company is in severe financial distress, exploring options like winding down operations or bankruptcy.
8-K
Financial Distress
December 12, 2025
High Impact
- Iterum Therapeutics received a Complete Response Letter (CRL) from the U.S. FDA for its antibiotic, sulopenem, indicating a delay in approval due to requests for more information/changes.
- Nasdaq notified Iterum that its stock no longer meets several key listing requirements, including minimum market value and share price, threatening potential delisting.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.